Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Animal models demonstrate that the C-cell effects of GLP-1 receptor agonists in rats and mice do not appear to be replicated in primates. However, randomized trials are not large enough or long ...

[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists ... is the guarantor of this work and, as such, had full ...

The once- and twice-daily GLP-1 RAs are now well established for their ... It has similar efficacy to other GLP1 agonists, with seemingly lower incidence of nausea. Another important distinction ...

In one of the most comprehensive analyses to date, researchers examined health records of nearly 216,000 veterans to map out the full range of effects associated with GLP-1 receptor agonists (GLP ...

Dietary supplements do not require FDA approval and don’t require ... to manage type 2 diabetes and/or aid in weight loss. These medications work by binding to GLP-1 receptors in the body, which ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Fortunately, large scale randomised trials with GLP-1RA-based therapies that yield greater weight loss are ongoing and several will report out in the next 1-4 years ... not been randomly allocated to ...